{
"ranked_hypotheses": [
{
"rank": 1,
"title": "SIRT3-Mediated Neuronal Mitochondrial Resilience",
"mechanism": "Neuronal SIRT3 deacetylates and activates mitochondrial enzymes (IDH2, SOD2, LCAD) during ketogenesis, preserving oxidation capacity while astrocytes lose ketone-producing enzyme expression with age.",
"target_gene": "SIRT3",
"confidence_score": 0.75,
"novelty_score": 0.65,
"feasibility_score": 0.70,
"impact_score": 0.85,
"composite_score": 0.755,
"testable_prediction": "SIRT3 neuron-specific knockout mice fed ketogenic diet will lose the ketone oxidation therapeutic window, showing accelerated cognitive decline compared to wild-type controls.",
"skeptic_concern": "SIRT3 activation alone may not restore ketone production; benefit depends on residual astrocytic substrate availability."
},
{
"rank": 2,
"title": "Astrocytic HMG-CoA Synthase II Production Deficit",
"mechanism": "Age-dependent decline in astrocytic HMG-CoA synthase II (HMGCS2) expression limits ketogenic flux at the production gate, creating substrate scarcity that persists even if transport capacity is restored.",
"target_gene": "HMGCS2",
"confidence_score": 0.60,
"novelty_score": 0.75,
"feasibility_score": 0.55,
"impact_score": 0.70,
"composite_score": 0.66,
"testable_prediction": "Astrocyte-specific Hmgcs2 knockdown in 3xTg-AD mice will reproduce the therapeutic window phenotype: declining βOHB production with preserved neuronal oxidation markers.",
"skeptic_concern": "HMGCS2 expression may be downstream of broader metabolic reprogramming, making single-gene intervention insufficient."
},
{
"rank": 3,
"title": "MCT1 Transport Capacity as Downstream Bottleneck",
"mechanism": "MCT1 downregulation in astrocytes creates a transport bottleneck limiting ketone export even when intracytoplasmic ketone synthesis remains detectable, making transport augmentation the optimal intervention.",
"target_gene": "SLC16A1",
"confidence_score": 0.55,
"novelty_score": 0.60,
"feasibility_score": 0.70,
"impact_score": 0.65,
"composite_score": 0.61,
"testable_prediction": "AAV-mediated astrocytic MCT1 overexpression in aged mice will restore brain ketone uptake to young-adult levels, quantified by 13C-βOHB PET imaging.",
"skeptic_concern": "Addresses only the export step; if astrocytic ketone production itself is the primary defect, transport augmentation will have limited therapeutic benefit."
}
],
"consensus_points": [
"A therapeutic window exists where neuronal ketone oxidation capacity exceeds astrocytic production capability",
"Molecular targeting must address either production, transport, or neuronal utilization to be therapeutically viable",
"The window timing varies by disease progression stage and requires temporal biomarker calibration"
],
"dissent_points": [
"Theorist emphasizes transport augmentation as primary intervention; Expert prioritizes neuronal resilience mechanisms; Skeptic questions whether production decline is the upstream driver"
],
"debate_summary": "The debate converged on a three-component model of the therapeutic window—production decline in astrocytes, substrate delivery via MCT1/MCT2, and neuronal utilization capacity via SIRT3—with the Expert ranking SIRT3-mediated neuronal resilience as highest translational priority due to existing pharmacologic pipelines, while acknowledging that the window may require combination therapy addressing multiple nodes. The Skeptic's critique that production-versus-export conflation remains the primary mechanistic uncertainty was incorporated into the ranking, elevating HMGCS2 (production) over MCT1 (transport) as the second priority."
}